Memorial Sloan Kettering Cancer Center
Fruquintinib significantly extends survival in refractory metastatic colorectal cancer
Treatment with fruquintinib resulted in a significant and clinically meaningful survival benefit when compared with placebo among patients with refractory metastatic colorectal cancer, according to data published in The Lancet.
New Leukemia & Lymphoma Society president to focus on drug development, health disparities
In his new role as president and CEO of The Leukemia & Lymphoma Society, pediatric hematologist oncologist E. Anders Kolb, MD, aims to expand his life’s work in advancing blood cancer research and therapies for patients of all ages.
Cabozantinib plus nivolumab effective in advanced non-clear cell RCC
Young children of patients with cancer more likely to have ‘critical unmet needs’
Parental cancer appeared associated with a higher odds of food insecurity, unaffordability of housing and other necessities, and barriers to transportation for medical care for young children.
NALIRIFOX extends OS, PFS for certain patients with pancreatic cancer
CHICAGO — First-line NALIRIFOX significantly extended in OS and PFS vs. gemcitabine and nab-paclitaxel among patients with treatment-naive metastatic pancreatic ductal adenocarcinoma, according to a study presented at ASCO Annual Meeting.
Cilta-cel CAR-T provides ‘unprecedented’ benefit for advanced multiple myeloma
CHICAGO — Ciltacabtagene autoleucel significantly extended PFS compared with standard therapy for adults with relapsed and lenalidomide-refractory multiple myeloma, results from the randomized phase 3 CARTITUDE-4 study showed.
Vorasidenib first ‘game changer’ in 20 years for patients with IDH-mutant grade 2 glioma
CHICAGO — Vorasidenib significantly improved PFS while delaying time to next intervention among certain patients with grade 2 isocitrate dehydrogenase 1- or 2-mutant glioma, according to data presented at ASCO Annual Meeting.
Neoadjuvant chemotherapy regimen shows durable survival benefit in rectal cancer
CHICAGO — Administering modified FOLFIRINOX chemotherapy before chemoradiation, surgery and adjuvant chemotherapy improved survival outcomes of patients with locally advanced rectal cancer, according to results of the PRODIGE 23 trial.
Some patients with locally advanced rectal cancer can be spared pelvic radiation
CHICAGO — Most patients with intermediate-risk rectal cancer can undergo curative-intent treatment without the need for pelvic radiation, according to study results presented during a press conference at ASCO Annual Meeting.
Nearly 1 in 4 academic oncologists report burnout
CHICAGO — Nearly one-fourth of academic oncologists surveyed reported feelings of burnout, with the highest rates among women and lesbian/gay/bisexual faculty, according to study results presented at ASCO Annual Meeting.